Immunity Against Measles in Korean Autologous Hematopoietic Stem Cell Transplant Recipients

The seropositivity of measles antibodies among 261 autologous stem cell transplant recipients (ASCTs) in Korea, assessed approximately 1-2 years after transplant (median, 11 months; interquartile range, 9-14), was significantly lower than age- and sex-matched control healthcare workers (83.1% [217/2...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Korean medical science 2024, 39(28), , pp.1-5
Main Authors: Jang, Hyeon Mu, Bae, Seongman, Jung, Jiwon, Cho, Hyungwoo, Yoon, Dok Hyun, Kim, Sung-Han
Format: Article
Language:English
Subjects:
Adult
Antibodies, Viral - blood
Brief Communication
Female
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Immunoglobulin G - blood
Male
Measles - immunology
Measles - prevention & control
Measles Vaccine - immunology
Measles virus - immunology
Middle Aged
Republic of Korea
Transplantation, Autologous
의학일반
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The seropositivity of measles antibodies among 261 autologous stem cell transplant recipients (ASCTs) in Korea, assessed approximately 1-2 years after transplant (median, 11 months; interquartile range, 9-14), was significantly lower than age- and sex-matched control healthcare workers (83.1% [217/261] vs. 90.3% [539/597], = 0.002). The findings underscore the vulnerability of adult ASCT recipients to measles. Clinicians should prioritize testing for measles IgG after ASCT and consider vaccination for ASCT recipients who remain seronegative 2 years after ASCT.
ISSN:1011-8934
1598-6357
1598-6357
DOI:10.3346/jkms.2024.39.e224